EUCTR2011-004377-84-FR进行中（未招募）1 期
A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of DCDT2980S in combination with rituximab or DCDS4501A in combination with rituximab in patients with relapsed or refractory B-cell non Hodgkin's lymphoma.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 230
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
入选标准
- •- Life expectancy of at least 12 weeks;
- •- Age = 18 years;
- •- History of histologically documented relapsed or refractory Grades 1-3a FL, or relapsed or refractory DLBCL;
- •- Must have at least one bi-dimensionally measurable lesion;
- •- Adequate hepatic, renal and cardiopulmonary function;
- •- For all men and women of childbearing potential use of adequate methods of contraception.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 30
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 90
排除标准
- •- Prior use of any monoclonal antibody, radioimmunoconjugate or antibody-drug conjugate within 4 weeks before Cycle 1 Day1;
- •- Treatment with radiotherapy, chemotherapy, immunotherapy, or an investigational anti-cancer agent within 2 weeks prior to Cycle 1 Day 1;
- •- Prior autologous stem cell transplant within 100 days prior to Cycle 1 Day 1;
- •- Prior allogeneic stem cell transplant;
- •- Eligibility for autologous stem cell transplant.
研究者
相似试验
进行中（未招募）
1 期
A study of pinatuzumab vedotin (DCDT2980S) combined with rituximab and polatuzumab vedotin (DCDS4501A) combined with rituximab or obinutuzumab in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma.EUCTR2011-004377-84-ITGenentech, Inc.230
进行中（未招募）
1 期
A study of pinatuzumab vedotin (DCDT2980S) combined with rituximab and polatuzumab vedotin (DCDS4501A) combined with rituximab or obinutuzumab in patients with relapsed or refractory B-cell Non-Hodgkin's Lymphoma.Follicular Non-Hodgkin’s Lymphoma (FL)Diffuse Large B-Cell Lymphoma (DLBCL)MedDRA version: 20.1 Level: LLT Classification code 10012857 Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10012855 Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) System Organ Class: 100000004864MedDRA version: 20.1 Level: LLT Classification code 10012856 Term: Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent System Organ Class: 100000004864MedDRA version: 20.0 Level: LLT Classification code 10067070 Term: Follicular B-cell non-Hodgkin's lymphoma System Organ Class: 100000004864EUCTR2011-004377-84-DEGenentech, Inc.230
已完成
2 期
A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of DCDT2980S in combination with rituximab or DCDS4501A in combination with rituximab in patients with relapsed or refractory B-cell non Hodgkin's lymphoma.Non Hodgkin's Lymphoma10025320NL-OMON39673Genentech Inc3
进行中（未招募）
1 期
A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with HER2 negative, ER+ metastatic breast cancer.Metastatic breast cancerEUCTR2014-004698-17-CZMedica Scientia Innovation Research (MedSIR)486
进行中（未招募）
1 期
A randomized, multicenter, open-label, phase II trial to evaluate the efficacy and safety of palbociclib in combination with fulvestrant or letrozole in patients with HER2 negative, ER+ metastatic breast cancer.Metastatic breast cancerEUCTR2014-004698-17-ESMedica Scientia Innovation Research (MedSIR)304